␤2-chimaerin, a member of the GTPase-activating proteins for the small GTP-binding protein p21Rac, possesses a single cysteine-rich domain with high homology to those implicated in phorbol ester and diacylglycerol binding in protein kinase C (PKC) isozymes. We have expressed ␤2-chimaerin in Sf9 insect cells using the baculovirus expression system and determined that, like PKCs, ␤2-chimaerin binds phorbol esters with high affinity in the presence of phosphatidylserine as a cofactor. Scatchard plot analysis using the radioligand [ 3 H]phorbol 12,13-dibutyrate revealed a dissociation constant of 1.9 ؎ 0.2 nM for ␤2-chimaerin. Likewise, ␤2-chimaerin is a high affinity receptor for the bryostatins, a class of atypical PKC activators. A detailed comparison of structure-activity relations using several phorbol ester analogs revealed striking differences in binding recognition between ␤2-chimaerin and PKC␣. Although the diacylglycerol 1-oleoyl-2-acetylglycerol binds with similar potency to both ␤2-chimaerin and PKC␣, the mezerein analog thymeleatoxin has 56-fold less affinity for binding to ␤2-chimaerin. To establish whether ␤2-chimaerin responds to phorbol esters in cellular systems, we overexpressed ␤2-chimaerin in COS-7 cells and monitored its subcellular distribution after phorbol ester treatment. Interestingly, as described previously for PKC isozymes, ␤2-chimaerin translocates from cytosolic to particulate fractions as a consequence of phorbol ester treatment. Our results demonstrate that ␤2-chimaerin is a novel target for the phorbol ester tumor promoters. The expansion of the family of phorbol ester receptors strongly suggests a potential for the "nonkinase" receptors as cellular mediators of the phorbol ester responses.
The phorbol esters and related diterpenes are natural compounds that are used widely as tumor promoters in animal models. The search for receptors for the phorbol esters led to the identification of protein kinase C (PKC) 1 as their target (1) (2) (3) (4) (5) . The complexity and heterogeneity in the biology of phorbol esters suggested the existence of multiple receptors, and 11 PKC isoforms have been identified so far: classic or calciumdependent isozymes (PKC ␣, ␤1, ␤2, and ␥), novel or calciumindependent isozymes (PKC ␦, ⑀, , , and ), and atypical isozymes (PKC and ) (6, 7) . The last group is unresponsive to the phorbol esters. DAG, the postulated endogenous activator of PKC, competes with phorbol esters for binding to PKC in in vitro assays, although its binding potency is lower than that of the most commonly used phorbol esters (8) . The cysteine-rich domains present at the NH 2 -terminal region of the PKCs are the binding sites for DAG/phorbol esters (9 -13) . Each of these 50-or 51-amino acid domains possesses the motif HX 12 CX 2 CX 13/14 CX 2 CX 4 HX 2 CX 7 C, where H is histidine, C is cysteine, and X is any other amino acid. This motif is duplicated in tandem in both the classic and novel PKCs and is present only once in the atypical PKCs. The cysteine-rich domains have been implicated in the association of PKC with membranes upon phorbol ester binding, a process referred to as translocation in intact cells. The molecular basis of this subcellular compartmentalization is currently the subject of intense research; recent studies on the structural aspects of translocation revealed that in PKC␦ the second cysteine-rich domain plays the predominant role in the translocation to membranes (14) .
Although it is widely assumed that phorbol esters mediate their responses through activation of PKC isozymes, two additional phorbol ester receptors have been identified so far: mammalian n-chimaerin and Caenorhabditis elegans Unc-13 (15, 16) . These novel receptors both possess a single copy of the cysteine-rich domain, suggesting that, as observed previously with PKC deletion mutants, only one copy of the motif is sufficient for high affinity binding of phorbol esters. The chimaerin family has expanded recently with the cloning of a spliced variant of n-(or ␣1)-chimaerin, namely, ␣2-chimaerin (17) , and the cloning of ␤1-and ␤2-chimaerins, two novel spliced variants from a second (␤) gene (18, 19) . Both members of the ␣-and ␤-chimaerins possess, in addition to the NH 2 -terminal cysteine-rich motif, a COOH-terminal region with high homology to BCR, the Breakpoint Cluster Region involved in the translocation of Philadelphia chromosome in chronic myelogenous leukemia. This domain in ␣-and ␤-chimaerins is completely unrelated to any kinase domain and has GTPaseactivating protein activity for p21Rac, a small GTP-binding protein involved in the control of cell morphology and cell growth (18, 20 -22) .
Both ␤1-and ␤2-chimaerin have identical cysteine-rich and GTPase-activating protein domains. ␤2-Chimaerin possesses an additional NH 2 -terminal SH2 domain of unknown function (19) . Although the cysteine-rich domains of ␤-chimaerins have a high degree of homology to those in PKC isozymes and nchimaerin, it is not known whether the ␤-chimaerins are receptors for the phorbol esters and DAG. It is noteworthy that single changes at several positions of the cysteine-rich domains in PKCs are sufficient to abolish completely or reduce substantially the binding of phorbol esters (13) . Moreover, not all of the proteins possessing similar cysteine-rich motifs in their structure are phorbol ester receptors (23, 24) . In this study we expressed ␤2-chimaerin as a prototype of the ␤-chimaerin family using the baculovirus expression system and showed that it binds phorbol esters and DAG with high affinity in the presence of phosphatidylserine as a cofactor. In addition, we found that phorbol esters translocate ␤2-chimaerin from cytosolic to particulate compartments in COS-7-transfected cells. The discovery of novel cellular phorbol ester receptors allows us to speculate that some of the biological responses of the phorbol esters could be mediated by the activation of PKC-independent pathways. (25) . PDBu, PMA, 4␣-PMA, mezerein, thymeleatoxin, (Ϫ)-indolactam V, prostratin, 12-deoxyphorbol 13-phenylacetate, and GF 109203X were purchased from LC Laboratories (Woburn, MA). 1-Oleoyl 2-acetylglycerol (OAG) was purchased from Avanti Polar Lipids (Pelham, AL). Phospholipids were obtained from Sigma. Cell culture reagents and media were obtained from Life Technologies, Inc. Reagents for expression and purification of recombinant GST-fusion proteins were purchased from Pharmacia Biotech Inc.
EXPERIMENTAL PROCEDURES

Materials-[
Cell Culture-Spodoptera frugiperda (Sf9) insect cells were cultured in spinner flasks at 27°C (without CO 2 ) in Grace's medium containing 10% fetal bovine serum, 50 g/ml gentamicin, and 2.5 g/ml Fungizone. COS-7 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin, and 100 g/ml streptomycin at 37°C in a humidified 5% CO 2 atmosphere.
Expression and Purification of Recombinant ␤2-Chimaerin from Sf9 Insect Cells-The full-length cDNA for ␤2-chimaerin was cloned using a polymerase chain reaction from human cerebellar cDNA (CLONTECH). The following oligonucleotides were used: 5Ј-GTCAGGCTCGAGG-GATCCATGCGTCTCCTCTCCAGCCTGTCC (XhoI and BamHI sites underlined) and 5Ј-GTCAGGACGCGTGAATTCGGATTAGAATAAAA-CGTCTTCG (MluI and EcoRI sites underlined), where the bases following the restriction sites correspond to the nucleotides 445-468 and 1827-1848 in the original sequence reported by Leung et al. (19) . The restriction sites were included to facilitate the subcloning into baculovirus, bacterial, and mammalian expression vectors. A fragment of 1.4 kilobases was cloned and ligated into pCRII using the TA cloning kit (Invitrogen) to generate pCRII-␤2. The polymerase chain reaction product was sequenced, and the sequence fully agreed with the original sequence (19) . A 1.4-kilobase BamHI-EcoRI fragment was isolated from pCRII-␤2 and subcloned in-frame into the baculovirus transfer vector pAcG2T (Pharmingen, San Diego), a vector designed for the expression of GSTfusion proteins in Sf9 insect cells. Recombinant baculoviruses were generated with the BaculoGold transfection kit (Pharmingen), as we have described previously for n-chimaerin (26) . High titer stocks (Ͼ10 8 plaque-forming units/ml) of the recombinant baculovirus were prepared in suspension cultures of Sf9 cells using standard techniques (27) . To express high levels of recombinant ␤2-chimaerin protein, Sf9 cells (1 liter) in spinner flasks were infected at a multiplicity of infection of 5 with the recombinant baculovirus. Cells were lysed by homogenization and sonication (lysis buffer: 50 mM Tris-HCl, pH 7.4; 5 mM EDTA, 1 g/ml aprotinin, 5 g/ml leupeptin, 5 g/ml 4-(2-aminoethyl)benzenesulfonyl fluoride, 1 M pepstatin A). The cell homogenate was centrifuged at 20,000 ϫ g for 20 min, the supernatant collected, and the GST-␤2-chimaerin bound to glutathione-Sepharose 4B beads using the standard protocol recommended by the manufacturer (Pharmacia). To cleave the GST partner, the GST-␤2-chimaerin bound to the beads was treated with thrombin for 4 h (4°C). Thrombin was removed with benzamidine-Sepharose 6B beads (Pharmacia). In some experiments, we used the GST-␤2-chimaerin fusion protein, generated by elution with 10 mM reduced glutathione from the glutathione-Sepharose 4B beads. Recombinant proteins were kept at Ϫ80°C.
Generation of ␤2-Chimaerin in Escherichia coli-The 1.4-kilobase BamHI-EcoRI fragment encoding the full-length ␤2-chimaerin cDNA was isolated from pCRII-␤2 and ligated in-frame into the bacterial expression vector pGEX-2TK (Pharmacia). Expression of the GST-fusion protein in XL-1 blue E. coli cells (Stratagene) was induced by the addition of 0.5 mM Isopropyl-␤-D-thiogalactoside after the bacteria reached an A 600 of about 0.5. After 5 h at 37°C, the cells were pelleted at 4,000 ϫ g, and the recombinant ␤2-chimaerin or GST-␤2-chimaerin was purified as described for insect cells.
Expression and Purification of PKC␣ and PKC␦-Recombinant PKC␣ and PKC␦ were expressed in Sf9 insect cells and purified as described previously (8) .
[ (28) , using 100 g/ml phosphatidylserine and 1 mM EGTA at 18°C (unless otherwise indicated). A detailed description of the binding assay methodology can be found elsewhere (8) tion assay described for [ 3 H]epibryostatin 4 (25) in a total volume of 250 l, as described in an earlier paper (29) .
Binding using total cellular lysates was carried out using a fixed concentration of [ 3 H]PDBu (15 nM). Sf9 cells or COS-7 cells in a six-well plate were lysed in 1 ml of lysis buffer. 50 l/tube of the total lysate (in triplicate) was used in the binding assay (30) .
Expression of ␤2-Chimaerin in COS-7 Cells-We have modified the eukaryotic expression vector pCR3 (Invitrogen) by inserting an 81-base pair cassette with XhoI and MluI restriction sites, an epitope or ⑀-tag, and a stop codon. We named this vector pCR3⑀. The ⑀-tag proved to work well for immunodetection with a commercial anti-PKC⑀ antibody (Life Technologies, Inc.) and, importantly, it does not affect subcellular localization in tagged phorbol ester receptors (14, 31) . A 1.4-kilobase XhoI-MluI fragment comprising the full-length ␤2-chimaerin was ligated in the pCR3⑀ vector to generate pCR3⑀-␤2. The plasmid pCR3⑀-␤2 was transfected into COS-7 cells using LipofectAMINE (Life Technologies, Inc.). The highest expression of ␤2-chimaerin was observed at 48 -72 h. Treatment of cells with PMA (0.001-10 M) for different times was performed 48 h after transfection. Cells were harvested into lysis buffer, lysed by sonication, and fractionated by centrifugation, as described by Szallasi et al. (32) . The cytosolic fraction was obtained by collection of the supernatant after centrifugation of the total lysate (1 h at 100,000 ϫ g at 4°C). The pellet was extracted for 1 h with 1% Triton X-100 in lysis buffer and subsequently centrifuged (1 h at 100,000 ϫ g at 4°C). The supernatant of this spin represents the Triton X-100-soluble particulate fraction (membrane-enriched), and the remaining pellet is the Triton X-100-insoluble fraction (cytoskeleton-enriched). Protein concentration was determined in each sample using the BioRad protein assay kit, and equal amounts of protein for each fraction were subjected to SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. Membranes were blocked with 5% milk in phosphate-buffered saline and subsequently immunostained with the anti-⑀-tag antibody. After stripping off the antibodies by incubation in 3.5 M MgCl 2 and phosphate-buffered saline for 30 min at 60°C, the membranes were blotted with a specific anti-PKC␣ antibody (Upstate Biotechnology, Inc., Lake Placid, NY) for detection of the endogenous PKC␣. Densitometric analysis was performed under condi- 
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tions that yield a linear response and analyzed using the NIH Image 1.52 program (33) .
RESULTS
Expression of ␤2-Chimaerin in Sf9
Cells-In this study we took advantage of the baculovirus expression system to generate ␤2-chimaerin as a GST-fusion protein. Using a multiplicity of infection of 5 plaque-forming units/cell, the highest levels of expression were obtained at about 60 h after infection (data not shown). Total lysates of Sf9 cells infected with either a recombinant ␤2-chimaerin baculovirus or a PKC␣ baculovirus (8) showed elevated [ 3 H]PDBu binding compared with noninfected Sf9 cells (Fig. 1B) . High levels of expression of GST-␤2-chimaerin were observed in Western blots using an anti-GST antibody (Pharmacia) (data not shown). GST-␤2-chimaerin was purified using glutathione-Sepharose 4B beads, and then ␤2-chimaerin was subsequently released from the GST fusion partner by cleavage with thrombin. A Coomassie Blue-stained gel of the recombinant purified ␤2-chimaerin is shown in Fig. 1A . About 1-2 mg of ␤2-chimaerin/liter of Sf9 cells was typically obtained, and the purity of the preparation was usually greater than 80%.
Binding of Phorbol Esters to Recombinant ␤2-ChimaerinChimaerins have a high degree of sequence identity with PKC isozymes at the level of the cysteine-rich domain (approximately 40% with PKC␣). We have determined previously that, similar to PKC␣, recombinant n-chimaerin expressed in baculovirus binds phorbol esters with high affinity (26) . Using [ 3 H]PDBu as a probe for phorbol ester binding, we have observed that ␤2-chimaerin also binds efficiently to the radioligand in the presence of a phospholipid cofactor (phosphatidylserine, 100 g/ml). As described earlier for PKC (8, 34) (Fig. 2A) . The presence of 0.1 mM calcium, a cofactor for the classic PKC isozymes, did not affect substantially the binding affinity (K d (8, 30) . ␤2-Chimaerin expressed in E. coli has a comparable binding affinity for , n ϭ 3) . The presence of the GST fusion partner did not change the affinity for
␤2-Chimaerin
To analyze receptor-ligand interactions, we quantitated competition of [ 3 H]PDBu binding with a range of analogs known to bind and activate PKC ( Table I ). The series of compounds used in this structure-activity analysis, in addition to possessing different biological properties in cellular and animal models, spanned a range of 3 orders of magnitude in binding affinity for PKC isozymes. Our previous studies revealed a specific pattern of recognition for these compounds by individual PKC isoforms (8) . Competition experiments with 12-deoxyphorbol 13-phenylacetate and 12-deoxyphorbol 13-acetate (prostratin), potent antipromoters in animal models, revealed somewhat lower affinities for ␤2-chimaerin than for PKC␣, as was the case for PDBu. Similarly, the incomplete tumor promoter mezerein bound with lower potency to ␤2-chimaerin. The tumor promoter thymeleatoxin, a mezerein analog, has a significantly lower affinity (approximately 56-fold) for ␤2-chimaerin. This difference is greater than that previously observed among classic and novel PKC isozymes (i.e. 20-fold lower affinity for PKC⑀ and compared with PKC␤1) (8) . It is noteworthy that differences in the binding affinity for thymeleatoxin between PKC␣ and n-chimaerin (26) or between PKC␦ and Unc-13 (13) were less than 2-fold. The indole alkaloid (Ϫ)-indolactam V showed similar binding affinity for ␤2-chimaerin and PKC␣. Likewise, the diacylglycerol OAG bound with similar affinity to both receptors. A representative competition experiment using OAG is shown in Fig. 2B . Structure-activity analysis was nearly identical in either Sf9-or E. coli-expressed ␤2-chimaerin (data not shown). These results clearly show that ␤2-chimaerin has a unique pattern of ligand recognition.
The bryostatins, macrocyclic lactones with an atypical spectrum of biological responses compared with those of the typical phorbol esters, also bound to ␤2-chimaerin with high affinity. Using the radioligand [ 3 H]bryostatin 1 and carrying out the assays in phosphatidylserine/Triton X-100, we determined a K d of 8.5 Ϯ 0.9 nM (n ϭ 3) for ␤2-chimaerin, about five times lower than that observed with PKC␣ (K d ϭ 1.6 Ϯ 0.1 nM, n ϭ 3) (Fig.  3) . (35) . Phosphatidylserine is the most effective phospholipid for supporting phorbol ester/DAG binding to PKC, n-chimaerin, and Unc-13 (26, 30, 36) . Specific [ 3 H]PDBu binding to ␤2-chimaerin was dependent on the concentration of phosphatidylserine used in the assay (Fig. 4) . The concentration of phosphatidylserine necessary for half-maximal binding activity was 1.4 Ϯ 0.3 g/ml (n ϭ 4). Using a fixed amount of total phospholipid and varying the proportion of phosphatidylserine, with the remainder being phosphatidylcholine, significant differences in cofactor requirement were observed between ␤2-chimaerin and PKC␣ (Fig. 5) . The EC 50 % (defined as the percent of phosphatidylserine required to reconstitute halfmaximal binding) for ␤2-chimaerin was 10.3 Ϯ 0.3% (n ϭ 3). Calcium (0.1 mM) did not affect the phosphatidylserine requirement for [ 3 H]PDBu binding to PKC has been reported to be dependent on calcium concentrations (36) . Likewise, we observed that the EC 50 % for PKC␣ was significantly higher in the absence of calcium (40.0 Ϯ 1.4%, n ϭ 3) than in the presence of calcium (EC 50 %ϭ 1.5 Ϯ 0.1%, n ϭ 3). Because the differences in phospholipid requirement could be due to the presence of the C2 domain (presumably involved in calcium binding) in PKC␣, we decided to perform similar reconstitution experiments using PKC␦, a calcium-independent PKC isozyme. In this latter case, phosphatidylserine requirements resemble those of ␤2-chimaerin and were not dependent on the presence or absence of calcium. Values of EC 50 % for reconstitution of binding to PKC␦ were 10.9 Ϯ 0.9% (n ϭ 3) in the absence of calcium and 9.6 Ϯ 1.1% (n ϭ 3) in the presence of calcium. As suggested by Newton and Keranen (37) , calcium increases the affinity of PKC for the acidic phospholipids. Our results support that concept but also suggest that the calcium effect is limited to calcium-dependent PKCs rather than to other calcium-independent phorbol ester receptors, such as the novel PKCs and chimaerins.
Phosphatidylserine Requirement for Phorbol Ester Binding to ␤2-Chimaerin-Early
␤2-Chimaerin as a Phorbol Ester Receptor
Redistribution of ␤2-Chimaerin in COS-7 Cells after Phorbol Ester Treatment-We have expressed ␤2-chimaerin in COS-7 cells using a tagging system described previously (⑀-tag). After transfection of pCR3⑀-␤2 into COS-7 cells, a band of the expected size (approximately 55 kDa) was detected with the anti ⑀-tag antibody, which was not detected in pCR3⑀-transfected or nontransfected cells (Fig. 6A) . COS-7 cells transfected with pCR3⑀-␤2 showed elevated levels of 
It is well established that phorbol ester treatment induces the redistribution of PKC isozymes from soluble to particulate fractions, a process referred to as translocation. In Fig. 7 we show that treatment of pCR3⑀-␤2-COS-transfected cells with PMA (3 M) induces a time-dependent redistribution of ␤2-chimaerin from soluble to both particulate fractions. As expected, endogenous PKC␣ also translocates from cytosolic to membrane and cytoskeletal fractions by PMA in a time-dependent manner.
A concentration-dependence analysis for the PMA effect revealed that higher concentrations were required for the translocation of ␤2-chimaerin than for PKC␣ (Fig. 8) . The ED 50 for removal of PKC␣ from the soluble fraction after 1 h of PMA treatment was 0.02 Ϯ 0.01 M, that is, in the same range previously reported (32, 33) . The ED 50 for removal of ␤2-chimaerin from the soluble fraction was approximately 50 times higher (1.0 Ϯ 0.1 M). This difference in potency for translocation between PKC␣ and ␤2-chimaerin was also observed after 6 h of PMA treatment; longer periods of incubation result in PKC␣ down-regulation (data not shown). To rule out any contribution of PKC in the PMA-induced redistribution of ␤2-chimaerin, we pretreated the cells with the selective PKC inhibitor bisindolylmaleimide GF 109203X (5 M) 30 min before PMA. A similar pattern of translocation for ␤2-chimaerin was observed in the presence of the PKC inhibitor, suggesting that the phorbol ester effect is not mediated by PKC but is rather a direct effect on ␤2-chimaerin.
No significant changes in the subcellular distribution of ␤2-chimaerin were observed by treatment with the inactive phorbol ester 4␣-PMA (Fig. 9, A and B ). An identical pattern of subcellular distribution of ␤2-chimaerin by PMA was observed when cells were pretreated with the protein synthesis inhibitor cycloheximide (20 g/ml, 30 min). Therefore, translocation is not the result of a gain in newly synthesized protein associated with membrane/cytoskeletal fractions (Fig. 9C) .
DISCUSSION
The presence of a cysteine-rich domain in the ␤-chimaerins, with high homology to the cysteine-rich domains present in PKC isozymes, suggested the possibility that this family of p21Rac GTPase-activating proteins was a candidate receptor for the phorbol ester tumor promoters and the second messenger DAG. Sequence alignment of ␤-chimaerins with known phorbol ester receptors revealed approximately 40% homology at the cysteine-rich domain with PKC isozymes. Likewise, the homology with cysteine-rich domains of n-(␣1)-chimaerin and Unc-13 is 93% and 42%, respectively. In this paper, our detailed studies of phorbol ester binding show that ␤2-chimaerin is indeed a high affinity phorbol ester/DAG receptor. Moreover, like the PKCs, ␤2-chimaerin translocates from soluble to particulate fractions after phorbol ester treatment.
By expressing ␤2-chimaerin in the baculovirus expression system we were able to generate high amounts of recombinant purified protein to perform a detailed analysis of the molecular interactions between phorbol ester analogs and this novel phorbol ester receptor. As we have reported previously with nchimaerin and Unc-13, a single cysteine-rich domain is sufficient for high affinity phorbol ester binding (26, 30 (8) . A thorough mutagenesis analysis at 25 positions of the second cysteine-rich domain of PKC␦ has revealed essential amino acids involved in ligand recognition. Those residues are highly conserved in the cysteine-rich domain of ␤-chimaerins, including the conserved cysteines and histidines, conserved hydrophobic amino acids (positions 3, 8, 20, 21, 22, 24, 36, 38 , and 46), proline 11, and glutamine 27 (13) . Several of those amino acids are missing or not conserved in cysteine-rich domains unable to bind phorbol esters, including those of atypical PKC, c-Raf, and Vav (23) . Although the cysteine-rich domain in ␤2-chimaerin clearly fulfills the structural requirements necessary for phorbol ester binding, the differences observed in structure-activity relations among PKC isozymes, n-chimaerin, ␤2-chimaerin, and Unc-13 suggest that specific residues within the domain may confer binding selectivity toward certain classes of ligands. A detailed comparison of ligand binding properties in this and our previous reports shows both remarkable similarities and striking differences among the individual phorbol ester receptors (see Refs. 8, 26, 29, and 30). We have found the most striking difference in ligand selectivity with thymeleatoxin, a tumor promoter of the mezerein family. Differences in binding affinities for thymeleatoxin by ␤2-chimaerin and PKC␣ are the highest reported so far for two individual phorbol ester receptors. It is interesting that DAG, the postulated activator of PKC isozymes, binds with similar affinities to classic and novel PKC isozymes, nchimaerin, ␤2-chimaerin, and Unc-13. The flexibility conferred by the rotatable bonds of the DAGs may allow a better accommodation within the binding site of the different cysteine-rich domains and therefore allow a correspondingly good interaction between the active residues of the pharmacophore and each protein binding site (8, 38) . Mutagenesis studies, as well as NMR or x-ray diffraction structural analysis of the different receptors, may give insight into the residues conferring these differences in ligand recognition and may permit rational design of selective agonists or antagonists.
The similar affinity for DAG among the different receptors suggests that non-PKC receptors might mediate cellular signaling pathways triggered by elevations in the levels of this lipophilic second messenger. One potential factor that might account for a differential regulation of the activity of the different phorbol ester/DAG receptors is the phospholipid/calcium requirement. At the intracellular level, such a difference in cofactor requirement might differentially regulate the association to membranes of the individual receptors. Other known PKC modulators, such as free fatty acids, may also play a role in the differential regulation of the phorbol ester receptors. Our experiments in COS-7 cells reveal differences in concentration and time dependence for the translocation of ␤2-chimaerin and PKC␣. The higher PMA concentration required for the translocation of ␤2-chimaerin could be related to its lower binding affinity relative to PKC␣. Studies of PKC translocation have revealed that individual PKC isoforms redistribute with different kinetics and concentration dependence. In keratinocytes, for example, PMA translocates PKC⑀ with 2 orders of magnitude higher potency compared with PKC␣ and ␦ (33). Structural differences among the different receptors conferring unique patterns of interactions with phorbol esters and phospholipids may regulate the association with membranes and/or the cytoskeleton. Recent studies (14) showed that the first and second cysteine-rich domains in PKC␦ have nonequivalent roles in translocation. A proline to glycine mutation in position 11 of the second cysteine-rich domain reduces the EC 50 for translocation by about 20-fold. Our studies demonstrate that a single cysteine-rich domain is sufficient for the phorbol estermediated translocation. The presence of a single cysteine-rich domain in ␤2-chimaerin may limit the stabilization of the ternary complex of protein-lipid-phorbol ester, and this may result in a reduced rate of translocation. We cannot rule out that interactions with specific proteins, such as receptors for activated C kinase or others anchoring proteins (39, 41) , contribute to the differential association to membranes and/or cytoskeleton compartments of individual DAG/phorbol ester receptors, as has been already shown for PKC. It may also be possible that subcellular localization of ␤2-chimaerin is regulated through the association of its NH 2 -terminal SH2 domain to phosphotyrosine proteins, a subject that we are currently investigating in our laboratory.
In summary, ␤-chimaerins represent a novel family of phorbol ester receptors. To our knowledge, this is the first report that phorbol ester receptors other than the PKC isozymes can be subjected to translocation by the phorbol esters. Subcellular compartmentalization after phorbol ester treatment or stimulation of receptors coupled to the elevation of the second messenger DAG may result in the association of chimaerins with specific chimaerin targets in the cell or in changes in chimaerin p21Rac-GTPase-activating protein activity. Recent observations showing that phorbol ester activation of n-chimaerin regulates p21Rac-mediated actin cytoskeleton reorganization (42) strongly support this hypothesis. It is predictable that the PKC isozymes are only one of several transducers of DAG signaling and phorbol ester actions in cellular systems. Alternative molecular approaches, including overexpression, knockouts, and dominant negatives of these novel phorbol ester receptors, will be essential to assess their role.
